...
首页> 外文期刊>Gene: An International Journal Focusing on Gene Cloning and Gene Structure and Function >Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reports
【24h】

Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reports

机译:ERCC1-C118T和-C8092A多态性与肺癌风险和肺癌患者患者的肺癌危险和存活率接受铂类化疗:基于39报告的汇总分析

获取原文
获取原文并翻译 | 示例

摘要

The published data on the predictive role of ERCC1 polymorphisms in lung cancer risk and survival of patients with advanced non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy remains inconsistent. The aim of this meta-analysis was to determine the role of ERCC1 gene polymorphisms (C118T and C8092A) in this clinical situation. Eligible studies were included and assessed for quality using multiple search strategies. Thirty-nine published papers involving 9615 cases (4606 with Stage III/IV disease) and 5542 controls were included in the analysis. Pooled odds ratios (OR) or hazard ratios (HR) with 95% confidence intervals (CI) were used to estimate risk. ERCC1-C118T was associated with lung cancer risk. The OR was 0.90 (95% CI: 0.81-0.99, p. = 0.043) in an additive genetic model (C allele vs. T allele) and 0.77 (95% CI: 0.63-0.95, p. = 0.013) in a recessive genetic model (CC/CT vs. TT). The corresponding risk was 0.74 (95% CI: 0.58-0.94, p. = 0.013) based on a homozygous comparison (CC vs. TT). No significant correlation was found for ERCC1 C8092A and there was no obvious relationship between ERCC1 C118T/C8092A polymorphisms and objective response to platinum-based chemotherapy. Overall survival (OS) of patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy was significantly related to ERCC1 C118T (HR: 1.29, 95% CI: 1.07-1.56, p. = 0.007, CT/TT vs. CC). There was no relationship between ERCC1 C8092A and survival (HR: 1.32, 95% CI: 0.84-2.10, p. = 0.23, CA/AA vs. CC). These findings suggest that ERCC1 C118T polymorphisms may serve as a biomarker for lung cancer risk and have prognostic value in patients with advanced non-small cell lung cancer (NSCLC) undergoing platinum-based treatment. Further studies with larger numbers of subjects from a worldwide arena are needed to validate the associations.
机译:关于ERCC1多态性在肺癌风险和先进的非小细胞肺癌(NSCLC)患者存活的上发表的数据仍然不一致。该荟萃分析的目的是确定ERCC1基因多态性(C118T和C8092A)在该临床情况下的作用。使用多种搜索策略将符合条件的研究包括并评估质量。在分析中,涉及9615例涉及9615例(4606阶段)和5542例对照的39篇发表论文。使用95%置信区间(CI)的汇集的差距(或)或危险比(HR)用于估算风险。 ERCC1-C118T与肺癌风险有关。在隐性遗传模型(C等位基因与T等位基因)和0.77(95%CI:0.63-0.95,p。= 0.013)中,在添加基因模型(C等位基因与T等位基因)和0.90(95%CI:0.81-0.99,p = 0.043)中遗传模型(CC / CT与TT)。基于纯合比(CC与TT),相应的风险为0.74(95%CI:0.58-0.94,p。= 0.013)。 ERCC1 C8092A没有发现显着的相关性,并且ERCC1 C118T / C8092A多态性与对铂化疗的客观反应无明显的关系。接受铂类化疗的非小细胞肺癌(NSCLC)患者的整体存活(OS)与ERCC1 C118T(HR:1.29,95%CI:1.07-1.56,p。= 0.007,CT / TT与VS有关。CC)。 ERCC1 C8092A和存活之间没有关系(HR:1.32,95%CI:0.84-2.10,p。= 0.23,CA / AA与CC)。这些发现表明,ERCC1 C118T多态性可以用作肺癌风险的生物标志物,并且对患有基于铂治疗的先进的非小细胞肺癌(NSCLC)患者具有预后价值。需要进一步研究来自全球竞技场的更多主题来验证协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号